肺癌患者的住院率高，主要由于疾病自然进展期间并发症的高风险。我们设计了一项回顾性、单中心、观察性研究，旨在确定住院肺癌患者30天死亡率的临床预测因子。收集了2017年1月1日至2022年1月1日期间巴尔马大学医院肺癌患者在肿瘤科住院的临床记录。截至数据截止日期，共纳入了251名连续入组患者。在单变量分析中，30天死亡率的基线临床预测因子包括东方合作肿瘤组织学研究组（ECOG PS）分级（≥2级 vs 0-1级：27.5% vs 14.8%，p=0.028）、高Blaylock Risk Assessment Screening Score（BRASS）（高 vs 中低：34.3% vs 11.9%，p<0.001）、疼痛存在（是 vs 否：24.4% vs 11.7%，p=0.009）、转移灶数目（≥3个 vs <3个：26.5% vs 13.4%，p=0.017）和骨转移存在（是 vs 否：29.0% vs 10.8%，p=0.001）。在多变量分析中，高BRASS与30天死亡率增加有显著关联（高 vs 中低；OR 2.87，95% CI 1.21 to 6.78，p=0.016）。我们的结果表明，基线较差的ECOG PS、高BRASS、疼痛存在、较高的肿瘤负担和骨转移存在可能是肺癌住院患者30天死亡率的临床预测因子。特别是，BRASS评分应作为一种简单的工具用于预测肺癌住院患者的30天死亡率。© 作者（或其雇主）2023。无商业再利用。详见权限和权利声明。BMJ出版。

Patients with lung cancer experience high rates of hospitalisation, mainly due to the high risk of complications that emerge during the natural history of the disease. We designed a retrospective, single-centre, observational study aimed at defining the clinical predictors of 30-day mortality in hospitalised patients with lung cancer.Clinical records from the first admission of patients with lung cancer to the oncology ward of the University Hospital of Parma from 1 January 2017 to 1 January 2022 were collected.251 consecutive patients were enrolled at the time of data cut-off. In the univariate analysis, baseline clinical predictors of 30-day mortality were Eastern Cooperative Oncology Group performance status (ECOG PS) (≥2 vs 0-1: 27.5% vs 14.8%, p=0.028), high Blaylock Risk Assessment Screening Score (BRASS) (high vs intermediate-low: 34.3% vs 11.9%, p<0.001), presence of pain (yes vs no: 24.4% vs 11.7%, p=0.009), number of metastatic sites (≥3 vs <3: 26.5% vs 13.4%, p=0.017) and presence of bone metastases (yes vs no: 29.0% vs 10.8%, p=0.001). In the multivariate analysis, high BRASS remained significantly associated with increased 30-day mortality (high vs intermediate-low; OR 2.87, 95% CI 1.21 to 6.78, p=0.016).Our results suggest that baseline poor ECOG PS, high BRASS, presence of pain, high tumour burden and presence of bone metastases could be used as clinical predictors of 30-day mortality in hospitalised patients with lung cancer. In particular, the BRASS scale should be used as a simple tool to predict 30-day mortality in hospitalised patients with lung cancer.© Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by BMJ.